List of Clorotekal drug patents

Clorotekal is owned by B Braun Medical Inc.

Clorotekal contains Chloroprocaine Hydrochloride.

Clorotekal has a total of 2 drug patents out of which 0 drug patents have expired.

Clorotekal was authorised for market use on 26 September, 2017.

Clorotekal is available in solution;intrathecal dosage forms.

Clorotekal can be used as a method for inducing a regional anaesthesia via intrathecal administration of a patented preservative free solution for injection (with a specific composition, ph, osmolality and density) containing 9-11 mg/ml chloroprocaine hcl.

The generics of Clorotekal are possible to be released after 11 December, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8969412 B BRAUN MEDICAL INC Use for a composition comprising chloroprocaine HCL, a new composition comprising chloroprocaine HCL and a method for its manufacture
Sep, 2026

(3 years from now)

US9504666 B BRAUN MEDICAL INC Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration
Dec, 2033

(10 years from now)

Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 September, 2017

Treatment: A method for inducing a regional anaesthesia via intrathecal administration of a patented preservative free solution for injection (with a specific composition, ph, osmolality and density) containing 9-11 mg/ml chloroprocaine hcl

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in